Physician profile
Gerald N Bock
NPI 1376649269
$510.60
in general payments reported to CMS, 2019-2025
10 companies · $84.53 in 2025
The $84.53 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.34 · 2020: $32.84 · 2021: $27.67 · 2022: $89.81 · 2023: $144 · 2024: $73.86 · 2025: $84.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226 · Education: $76.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.59 |
| Education | $76.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $108.62 | 2023-2025 | |
| Galderma Laboratories, L.P. | $105.25 | 2020-2022 | |
| Janssen Biotech, INC. | $74.78 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $52.98 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $41.15 | 2020-2023 | Dupixent |
| Genzyme Corporation | $37.37 | 2024 | |
| Revance Therapeutics, INC. | $36.49 | 2024 | Daxxify |
| Merz North America, INC. | $26.29 | 2023 | Xeomin |
| Abbvie INC. | $14.37 | 2021 | |
| Allergan, INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.